<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00996736</url>
  </required_header>
  <id_info>
    <org_study_id>H9332-33965-02</org_study_id>
    <secondary_id>U10EY018573-01A1</secondary_id>
    <nct_id>NCT00996736</nct_id>
  </id_info>
  <brief_title>Mycotic Ulcer Treatment Trial I</brief_title>
  <acronym>MUTT I</acronym>
  <official_title>Mycotic Ulcer Treatment Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aravind Eye Hospitals, India</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if natamycin or voriconazole results in better
      visual outcomes in fungal corneal ulcers, especially visual acuity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fungal corneal ulcers tend to have very poor outcomes with commonly used treatments. There
      has only been a single randomized trial of anti-fungal therapy for mycotic keratitis, and no
      new ocular anti-fungal medications have been approved by the FDA since the 1960s. The
      triazole voriconazole has recently become the treatment of choice for systemic fungal
      infections such as pulmonary aspergillosis. The use of topical ophthalmic preparations of
      voriconazole has been described in numerous case reports, however there has been no
      systematic attempt to determine whether it is more or less clinically effective than
      natamycin. Additionally, there have been many case reports of the use of oral voriconazole in
      the treatment of fungal corneal ulcers, however there has been no systematic attempt to
      determine if it improves outcomes in severe ulcers.

      This study is a randomized, double-masked, placebo-controlled trial to determine if the use
      natamycin or voriconazole results in better outcomes for fungal corneal ulcers. 368 fungal
      corneal ulcers with baseline visual acuity between 6/12 (20/40, logMAR 0.3) and 6/120
      (20/400, logMAR 1.3) presenting to the Aravind Eye Hospitals and the UCSF Proctor Foundation
      will be randomized to receive either topical natamycin or topical voriconazole. The primary
      outcome is best spectacle-corrected logMAR visual acuity three months after enrollment, using
      best spectacle-corrected enrollment visual acuity as a co-variate.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Spectacle-corrected logMAR Visual Acuity</measure>
    <time_frame>3 months from enrollment</time_frame>
    <description>The primary analysis is best spectacle-corrected logMAR (logarithm of the Minimum Angle or Resolution) visual acuity, correcting for enrollment BSCVA and treatment arm in a multiple linear regression model. The pre-specified non-inferiority margin is less than 1.5 lines logMAR acuity. (Adjusted three-month visual acuity confidence bounds for the difference between the voriconazole and natamycin groups which meet or exceed 0.15 logMAR units would not permit noninferiority to be declared.) Note that this design also allows declaration of superiority (2-sided alpha of 0.05, corrected for an interim analysis).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Spectacle-corrected logMAR Visual Acuity</measure>
    <time_frame>3 weeks after enrollment</time_frame>
    <description>Best spectacle-corrected logMAR (logarithm of the Minimum Angle of Resolution) visual acuity at 3 weeks after enrollment, adjusting for enrollment BSCVA and treatment arm in a multiple linear regression model</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hard Contact Lens-corrected Visual Acuity Measured in logMAR</measure>
    <time_frame>3 months after enrollment</time_frame>
    <description>Hard contact lens-corrected visual acuity measured in logMAR (logarithm of the Minimum Angle of Resolution) 3 months after enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Size of Infiltrate/Scar</measure>
    <time_frame>3 weeks and 3 months after enrollment</time_frame>
    <description>Size of infiltrate/scar at 3 weeks and 3 months after enrollment, using enrollment infiltrate scar/size as a covariate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of Epithelial Defect</measure>
    <time_frame>From enrollment to the time of resolution of epithelial defect</time_frame>
    <description>Time in days from enrollment to resolution of epithelial defect. For those subjects with more than 21 days to resolution, 21 days was used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Inhibitory Concentration of Isolates</measure>
    <time_frame>3 months after enrollment</time_frame>
    <description>Minimum inhibitory concentration (50th percentile) of fungal isolates to natamycin and voriconazole</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological Cure at 6 Days</measure>
    <time_frame>7 days after enrollment</time_frame>
    <description>Microbiological cure defined as no fungal growth on culture at 6 (+/-1) days from enrollment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">323</enrollment>
  <condition>Corneal Ulcer</condition>
  <condition>Eye Infections, Fungal</condition>
  <arm_group>
    <arm_group_label>Topical Natamycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical Voriconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Natamycin</intervention_name>
    <description>5% natamycin plus 0.02% preservative, one drop to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until 3 weeks after enrollment.</description>
    <arm_group_label>Topical Natamycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voriconazole</intervention_name>
    <description>1% voriconazole plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.</description>
    <arm_group_label>Topical Voriconazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of a corneal ulcer at presentation

          -  Evidence of filamentous fungus on smear (KOH wet mount, Giemsa, or Gram stain)

          -  Visual acuity between 6/12 (20/40, logMAR 0.3) and 6/120 (20/400, logMAR 1.3)

          -  The patient must be able to verbalize a basic understanding of the study after it is
             explained to the patient, as determined by physician examiner. This understanding must
             include a commitment to return for follow-up visits.

          -  Willingness to be treated as an inpatient or to be treated as an outpatient and return
             every 3 days +/- 1 day until re-epithelialization and every week to receive fresh
             medication for 3 weeks

          -  Appropriate consent

        Exclusion Criteria:

          -  Impending perforation

          -  Evidence of bacteria on Gram stain at the time of enrollment

          -  Evidence of acanthamoeba by stain

          -  Evidence of herpetic keratitis by history or exam

          -  Corneal scar not easily distinguishable from current ulcer

          -  Age less than 16 years (before 16th birthday)

          -  Bilateral ulcers

          -  Previous penetrating keratoplasty in the affected eye

          -  Pregnancy (by history or urine test) or breast feeding (by history)

          -  Acuity worse than 6/60 (2/200) in the fellow eye (note that any acuity, uncorrected,
             corrected, pinhole, or BSCVA 6/60 or better qualifies for enrollment)

          -  Acuity worse than 6/120 (20/400) or better than 6/12 (20/40) in the study eye (note
             that any acuity, uncorrected, corrected, pinhole, or BSCVA can be used for enrollment)

          -  Known allergy to study medications (antifungal or preservative)

          -  No light perception in the affected eye

          -  Not willing to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>NV Prajna, DNB, FRC Ophth</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aravind Eye Hospitals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nisha Acharya, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Proctor Foundation, UCSF</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tom Lietman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Proctor Foundation, UCSF</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Proctor Foundation, UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aravind Eye Hospitals</name>
      <address>
        <city>Madurai</city>
        <state>Tamil Nadu</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aravind Eye Hospital</name>
      <address>
        <city>Pondicherry</city>
        <state>Tamil Nadu</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Prajna NV, Krishnan T, Mascarenhas J, Rajaraman R, Prajna L, Srinivasan M, Raghavan A, Oldenburg CE, Ray KJ, Zegans ME, McLeod SD, Porco TC, Acharya NR, Lietman TM; Mycotic Ulcer Treatment Trial Group. The mycotic ulcer treatment trial: a randomized trial comparing natamycin vs voriconazole. JAMA Ophthalmol. 2013 Apr;131(4):422-9.</citation>
    <PMID>23710492</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2009</study_first_submitted>
  <study_first_submitted_qc>October 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2009</study_first_posted>
  <results_first_submitted>July 26, 2013</results_first_submitted>
  <results_first_submitted_qc>October 18, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 11, 2013</results_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Thomas M. Lietman</investigator_full_name>
    <investigator_title>Professor in Residence</investigator_title>
  </responsible_party>
  <keyword>Fungal Infections</keyword>
  <keyword>Eye Disease</keyword>
  <keyword>Fungal Keratitis</keyword>
  <keyword>Visual Acuity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Corneal Ulcer</mesh_term>
    <mesh_term>Eye Infections</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Eye Infections, Fungal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Voriconazole</mesh_term>
    <mesh_term>Natamycin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between April 3, 2010, and December 31, 2011, patients were recruited from the Cornea Clinics at the Aravind Eye Care Hospitals in Madurai, Pondicherry, and Coimbatore in Tamil Nadu, India.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Topical Natamycin</title>
        </group>
        <group group_id="P2">
          <title>Topical Voriconazole</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="162"/>
                <participants group_id="P2" count="161"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>3-week Visit</title>
              <participants_list>
                <participants group_id="P1" count="155">149 visited within pre-specified 3-week window (2.5-5 weeks); 6 had a second visit not within window</participants>
                <participants group_id="P2" count="151">144 visited within pre-specified 3-week window (2.5-5 weeks); 7 had a second visit not within window</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>3-month Visit</title>
              <participants_list>
                <participants group_id="P1" count="146"/>
                <participants group_id="P2" count="146"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="141"/>
                <participants group_id="P2" count="143"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Visit not within 3-month window</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Topical Natamycin</title>
        </group>
        <group group_id="B2">
          <title>Topical Voriconazole</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="162"/>
            <count group_id="B2" value="161"/>
            <count group_id="B3" value="323"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" lower_limit="39" upper_limit="58"/>
                    <measurement group_id="B2" value="45" lower_limit="38" upper_limit="55"/>
                    <measurement group_id="B3" value="47" lower_limit="39" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="162"/>
                    <measurement group_id="B2" value="161"/>
                    <measurement group_id="B3" value="323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Best Spectacle-corrected logMAR Visual Acuity</title>
        <description>The primary analysis is best spectacle-corrected logMAR (logarithm of the Minimum Angle or Resolution) visual acuity, correcting for enrollment BSCVA and treatment arm in a multiple linear regression model. The pre-specified non-inferiority margin is less than 1.5 lines logMAR acuity. (Adjusted three-month visual acuity confidence bounds for the difference between the voriconazole and natamycin groups which meet or exceed 0.15 logMAR units would not permit noninferiority to be declared.) Note that this design also allows declaration of superiority (2-sided alpha of 0.05, corrected for an interim analysis).</description>
        <time_frame>3 months from enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topical Natamycin</title>
          </group>
          <group group_id="O2">
            <title>Topical Voriconazole</title>
          </group>
        </group_list>
        <measure>
          <title>Best Spectacle-corrected logMAR Visual Acuity</title>
          <description>The primary analysis is best spectacle-corrected logMAR (logarithm of the Minimum Angle or Resolution) visual acuity, correcting for enrollment BSCVA and treatment arm in a multiple linear regression model. The pre-specified non-inferiority margin is less than 1.5 lines logMAR acuity. (Adjusted three-month visual acuity confidence bounds for the difference between the voriconazole and natamycin groups which meet or exceed 0.15 logMAR units would not permit noninferiority to be declared.) Note that this design also allows declaration of superiority (2-sided alpha of 0.05, corrected for an interim analysis).</description>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" lower_limit="0.30" upper_limit="0.48"/>
                    <measurement group_id="O2" value="0.57" lower_limit="0.48" upper_limit="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The pre-specified non-inferiority margin is less than 1.5 lines logMAR acuity. (Adjusted three-month visual acuity confidence bounds for the difference between the voriconazole and natamycin groups which meet or exceed 0.15 logMAR units would not permit noninferiority to be declared.) Note that this design also allows declaration of superiority (2-sided alpha of 0.05, corrected for an interim analysis).</non_inferiority_desc>
            <p_value>0.006</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.30</ci_lower_limit>
            <ci_upper_limit>-0.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Spectacle-corrected logMAR Visual Acuity</title>
        <description>Best spectacle-corrected logMAR (logarithm of the Minimum Angle of Resolution) visual acuity at 3 weeks after enrollment, adjusting for enrollment BSCVA and treatment arm in a multiple linear regression model</description>
        <time_frame>3 weeks after enrollment</time_frame>
        <population>306 total subjects (155 in natamycin arm, 151 in voriconazole arm) returned after enrollment for a second visit, but only 293 of those (149 in natamycin arm and 144 in voriconazole arm) visited within the 3-week window (2.5-5 weeks). Only those who visited within the window were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Topical Natamycin</title>
          </group>
          <group group_id="O2">
            <title>Topical Voriconazole</title>
          </group>
        </group_list>
        <measure>
          <title>Best Spectacle-corrected logMAR Visual Acuity</title>
          <description>Best spectacle-corrected logMAR (logarithm of the Minimum Angle of Resolution) visual acuity at 3 weeks after enrollment, adjusting for enrollment BSCVA and treatment arm in a multiple linear regression model</description>
          <population>306 total subjects (155 in natamycin arm, 151 in voriconazole arm) returned after enrollment for a second visit, but only 293 of those (149 in natamycin arm and 144 in voriconazole arm) visited within the 3-week window (2.5-5 weeks). Only those who visited within the window were included in the analysis.</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" lower_limit="0.42" upper_limit="0.57"/>
                    <measurement group_id="O2" value="0.63" lower_limit="0.56" upper_limit="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hard Contact Lens-corrected Visual Acuity Measured in logMAR</title>
        <description>Hard contact lens-corrected visual acuity measured in logMAR (logarithm of the Minimum Angle of Resolution) 3 months after enrollment</description>
        <time_frame>3 months after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topical Natamycin</title>
          </group>
          <group group_id="O2">
            <title>Topical Voriconazole</title>
          </group>
        </group_list>
        <measure>
          <title>Hard Contact Lens-corrected Visual Acuity Measured in logMAR</title>
          <description>Hard contact lens-corrected visual acuity measured in logMAR (logarithm of the Minimum Angle of Resolution) 3 months after enrollment</description>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" lower_limit="0.11" upper_limit="0.26"/>
                    <measurement group_id="O2" value="0.30" lower_limit="0.22" upper_limit="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Size of Infiltrate/Scar</title>
        <description>Size of infiltrate/scar at 3 weeks and 3 months after enrollment, using enrollment infiltrate scar/size as a covariate</description>
        <time_frame>3 weeks and 3 months after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topical Natamycin</title>
          </group>
          <group group_id="O2">
            <title>Topical Voriconazole</title>
          </group>
        </group_list>
        <measure>
          <title>Size of Infiltrate/Scar</title>
          <description>Size of infiltrate/scar at 3 weeks and 3 months after enrollment, using enrollment infiltrate scar/size as a covariate</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 weeks from enrollment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.30" lower_limit="3.15" upper_limit="3.48"/>
                    <measurement group_id="O2" value="3.44" lower_limit="3.29" upper_limit="3.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months from enrollment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.31" lower_limit="3.15" upper_limit="3.48"/>
                    <measurement group_id="O2" value="3.52" lower_limit="3.35" upper_limit="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Resolution of Epithelial Defect</title>
        <description>Time in days from enrollment to resolution of epithelial defect. For those subjects with more than 21 days to resolution, 21 days was used.</description>
        <time_frame>From enrollment to the time of resolution of epithelial defect</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topical Natamycin</title>
          </group>
          <group group_id="O2">
            <title>Topical Voriconazole</title>
          </group>
        </group_list>
        <measure>
          <title>Time to Resolution of Epithelial Defect</title>
          <description>Time in days from enrollment to resolution of epithelial defect. For those subjects with more than 21 days to resolution, 21 days was used.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.50" spread="7.60"/>
                    <measurement group_id="O2" value="11.50" spread="7.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minimum Inhibitory Concentration of Isolates</title>
        <description>Minimum inhibitory concentration (50th percentile) of fungal isolates to natamycin and voriconazole</description>
        <time_frame>3 months after enrollment</time_frame>
        <population>The population for analysis included only those subjects with positive fungal cultures and for whom Minimum Inhibitory Concentrations were available (108 subjects who were randomized to natamycin and 113 who were randomized to voriconazole).</population>
        <group_list>
          <group group_id="O1">
            <title>Topical Natamycin</title>
          </group>
          <group group_id="O2">
            <title>Topical Voriconazole</title>
          </group>
        </group_list>
        <measure>
          <title>Minimum Inhibitory Concentration of Isolates</title>
          <description>Minimum inhibitory concentration (50th percentile) of fungal isolates to natamycin and voriconazole</description>
          <population>The population for analysis included only those subjects with positive fungal cultures and for whom Minimum Inhibitory Concentrations were available (108 subjects who were randomized to natamycin and 113 who were randomized to voriconazole).</population>
          <units>Î¼g/ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="2" lower_limit="1" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbiological Cure at 6 Days</title>
        <description>Microbiological cure defined as no fungal growth on culture at 6 (+/-1) days from enrollment</description>
        <time_frame>7 days after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topical Natamycin</title>
          </group>
          <group group_id="O2">
            <title>Topical Voriconazole</title>
          </group>
        </group_list>
        <measure>
          <title>Microbiological Cure at 6 Days</title>
          <description>Microbiological cure defined as no fungal growth on culture at 6 (+/-1) days from enrollment</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Topical Natamycin</title>
        </group>
        <group group_id="E2">
          <title>Topical Voriconazole</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction or stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Corneal perforation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Therapeutic penetrating keratoplasty</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Corneal perforation and/or TPK</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Increase in hypopyon (&gt;2mm)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Increase in infiltrate size &gt; 50%</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Progressive corneal thinning, &lt;=50% of enrollment thickness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Thomas Lietman</name_or_title>
      <organization>F.I. Proctor Foundation, University of Califonia, San Francisco</organization>
      <phone>415-502-2662</phone>
      <email>tom.lietman@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

